Companies BRAINSTORM CELL THERAPEUTICS INC.
BRAINSTORM CELL THERAPEUTICS (BCLI): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me BRAINSTORM CELL THERAPEUTICS INC.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,117,966FY2022
- $1,128,795FY2023
- $750,303FY2024
CEO total pay was $750,303 in fiscal 2024, down from $1,128,795 in fiscal 2023.
FY2024: salary $387,500 · bonus $121,654 · stock awards $100,715
Order BCLI
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chaim Lebovits | $387,500 | $121,654 | $100,715 | — | — | — | $140,434 | $750,303 |
| Chief Executive Officer & President | ||||||||
| Ibrahim Dagher | 294,000 | 103,750 | 71,855 | — | — | — | 28,973 | 498,578 |
| Executive Vice President, Chief Medical Officer | ||||||||
| Stacy Lindborg | 125,947 | 100,000 | 79,839 | — | — | — | 40,589 | 346,375 |
| Former Co-Chief Executive Officer | ||||||||
| Uri Yablonka | 151,390 | 0 | 36,111 | — | — | — | 78,637 | 266,138 |
| Executive Vice President, Chief Business Officer, Secretary and Director | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Chaim Lebovits | $750,303 | $1,128,795 | $1,117,966 | ↓ −378,492 |
| Ibrahim Dagher | 498,578 | — | — | — |
| Stacy Lindborg | 346,375 | 1,007,725 | 851,543 | ↓ −661,350 |
| Uri Yablonka | 266,138 | 247,055 | — | ↑ +19,083 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is not explicitly detailed in a dedicated section, but the GNC Committee is responsible for reviewing and approving compensation programs to ensure they do not create risks reasonably likely to have a material adverse effect on the company. The Committee annually reviews and approves corporate goals relevant to CEO compensation and evaluates performance against these goals to set compensation levels.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chaim Lebovits | RSU | 520 | — | $1,180 |
| Chaim Lebovits | RSU | 1,039 | — | 2,360 |
| Chaim Lebovits | RSU | 1,559 | — | 3,540 |
| Ibrahim Dagher | Option | 3,666 | 25.95 | — |
| Yablonka | RSU | 7,295 | — | 16,560 |
| Ibrahim Dagher | RSU | 14,516 | — | 32,951 |
| Lindborg | RSU | 16,129 | — | 36,613 |
| Chaim Lebovits | RSU | 20,347 | — | 46,188 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Menghisteab BairuIndependent · Audit | $60,000 | $0 | $0 | — | — | $60,000 |
| Dr. Anthony PolverinoIndependent · GNC | 0 | 0 | 0 | — | — | 0 |
| Mr. Nir NaorIndependent · Audit (Chair) · GNC | 0 | 0 | 0 | — | — | 0 |
| Prof. Jacob FrenkelIndependent · Board Chair | 0 | 0 | 0 | — | — | 0 |
| Dr. Irit ArbelIndependent · GNC (Chair) · Audit | 0 | 0 | 0 | — | — | 0 |
| Mr. Uri YablonkaEmployee director | — | — | — | — | — | 0 |
| Dr. Stacy LindborgIndependent · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $0 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $60,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $60,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names BRAINSTORM CELL THERAPEUTICS as a peer
Companies that benchmark against BCLI
No companies currently name BCLI as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BRAINSTORM CELL THERAPEUTICS INC. | 2024 | Chaim Lebovits | $387,500 | $100,715 | — | — | $750,303 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (14 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Chaim Lebovits. DEF 14A, filed 2025-05-16. Section “Executive Compensation”. As printed: 750,303. View filing ↗
- Section 01, Ibrahim Dagher. DEF 14A, filed 2025-05-16. Section “Executive Compensation”. As printed: 498,578. View filing ↗
- Section 01, Stacy Lindborg. DEF 14A, filed 2025-05-16. Section “Executive Compensation”. As printed: 346,375. View filing ↗
- Section 01, Uri Yablonka. DEF 14A, filed 2025-05-16. Section “Executive Compensation”. As printed: 266,138. View filing ↗
- Section 08, Dr. Menghisteab Bairu. DEF 14A, filed 2025-05-16. Section “Director Compensation”. As printed: 60,000. View filing ↗
- Section 08, Dr. Anthony Polverino. DEF 14A, filed 2025-05-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Mr. Nir Naor. DEF 14A, filed 2025-05-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Prof. Jacob Frenkel. DEF 14A, filed 2025-05-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Dr. Irit Arbel. DEF 14A, filed 2025-05-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Mr. Uri Yablonka. DEF 14A, filed 2025-05-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Dr. Stacy Lindborg. DEF 14A, filed 2025-05-16. Section “Director Compensation”. As printed: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 60,000 + equity 0 + all other 0 = 60,000, summed across the director compensation table rows.
- BRAINSTORM CELL THERAPEUTICS INC. (subject), Section 10b CEO total. DEF 14A, filed 2025-05-16. CEO total compensation as printed in BRAINSTORM CELL THERAPEUTICS INC.'s own proxy. As printed: 750,303. View filing ↗